ICD Primary prevention trials: Difference between revisions

From Textbook of Cardiology
Jump to navigation Jump to search
No edit summary
No edit summary
 
(3 intermediate revisions by the same user not shown)
Line 1: Line 1:
placeholder
{| class="wikitable" border="1"
{| class="wikitable" border="1"
|-
|-
! colspan="6" | TABLE 1. Overview of the Major Randomized Controlled Clinical Trials of ICD Therapy for Primary Prevention of Sudden Cardiac Death in Ischemic Cardiomyopathy
! colspan="6" | Overview of the Major Randomized Controlled Clinical Trials of ICD Therapy for Primary Prevention of SCD in Ischemic Cardiomyopathy<cite>Passman</cite>
|-
|-
! Study
! Study
Line 12: Line 10:
! Main Finding
! Main Finding
|-
|-
| MADIT I<cite>35</cite>
| '''MADIT I'''<cite>35</cite>
| Prior MI, EF ≤35%, NSVT, inducible and nonsuppressible VT on EPS, NYHA class I–III
| Prior MI, EF ≤35%, NSVT, inducible and nonsuppressible VT on EPS, NYHA class I–III
| align="center" | 196
| align="center" | 196
Line 20: Line 18:
mortality with ICD (''P''=0.009); absolute RR 23%
mortality with ICD (''P''=0.009); absolute RR 23%
|-
|-
| CABG-PATCH<cite>36</cite>
| '''CABG-PATCH'''<cite>36</cite>
| EF <35%, abnormal SAECG, elective CABG
| EF <35%, abnormal SAECG, elective CABG
| align="center" | 900
| align="center" | 900
Line 28: Line 26:


|-
|-
| MUSTT<cite>37</cite>
| '''MUSTT'''<cite>37</cite>
| Prior MI, EF ≤40%, NSVT, inducible VT on EPS
| Prior MI, EF ≤40%, NSVT, inducible VT on EPS
| align="center" | 704  
| align="center" | 704  
Line 36: Line 34:


|-
|-
| MADIT II<cite>39</cite>
| '''MADIT II'''<cite>39</cite>
| Prior MI≤1 month, EF≤30%, NYHA class I–III
| Prior MI≤1 month, EF≤30%, NYHA class I–III
| align="center" | 1232
| align="center" | 1232
Line 44: Line 42:


|-
|-
| DINAMIT<cite>38</cite>
| '''DINAMIT'''<cite>38</cite>
| Recent (6–40 days) MI, EF≤35%, abnormal HRV or elevated average HR on 24-h Holter, NYHA class I–III
| Recent (6–40 days) MI, EF≤35%, abnormal HRV or elevated average HR on 24-h Holter, NYHA class I–III
| align="center" | 674
| align="center" | 674
Line 52: Line 50:


|-
|-
| SCD-HeFT<cite>34</cite>
| '''SCD-HeFT'''<cite>34</cite>
| EF≤35%, (ischemic or nonischemic) NYHA class II–III
| EF≤35%, (ischemic or nonischemic) NYHA class II–III
| align="center" | 2521
| align="center" | 2521
Line 65: Line 63:
==References==
==References==
<biblio>
<biblio>
#34 Bardy G, Lee KL, Mark D, Poole J, Packer D, Boineau R, Domanski M, Troutman R, Anderson J, Johnson G, McNulty S, Clapp-Channing N, Davidson-Ray L, Fraulo E, Fishbein D, Luceri R, Ip J. Amiodarone or an implantable cardioverter- defibrillator for congestive heart failure. ''N Engl J Med.'' 2005;352:225–237.
#Passman pmid=17664385
#34 pmid=15659722
#35 Moss A, Hall W, Cannom D, Daubert J, Higgins S, Klein H, Levine J, Saksena S, Waldo A, Wilber D, Brown M, Heo M; Multicenter Automatic Defibrillator Implantation Trial Investigators. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. ''N Engl J Med.'' 1996;335:1933–1940.
#35 Moss A, Hall W, Cannom D, Daubert J, Higgins S, Klein H, Levine J, Saksena S, Waldo A, Wilber D, Brown M, Heo M; Multicenter Automatic Defibrillator Implantation Trial Investigators. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. ''N Engl J Med.'' 1996;335:1933–1940.
#36 Bigger J; Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. ''N Engl J Med.'' 1997;337:1569 –1575.
#36 Bigger J; Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. ''N Engl J Med.'' 1997;337:1569 –1575.

Latest revision as of 19:30, 15 January 2012

Overview of the Major Randomized Controlled Clinical Trials of ICD Therapy for Primary Prevention of SCD in Ischemic Cardiomyopathy[1]
Study Inclusion Criteria Number Randomized Control Group Primary Point Main Finding
MADIT I[2] Prior MI, EF ≤35%, NSVT, inducible and nonsuppressible VT on EPS, NYHA class I–III 196 Conventional therapy All-cause mortality 54% RRR in all-cause

mortality with ICD (P=0.009); absolute RR 23%

CABG-PATCH[3] EF <35%, abnormal SAECG, elective CABG 900 Conventional therapy All-cause mortality No difference in all-cause mortality
MUSTT[4] Prior MI, EF ≤40%, NSVT, inducible VT on EPS 704 EP-guided antiarrhythmic therapy or conventional therapy Cardiac arrest or death due to arrhythmia 60% RRR in all-cause mortality with ICD (P=0.001); absolute RR 31%
MADIT II[5] Prior MI≤1 month, EF≤30%, NYHA class I–III 1232 Conventional therapy All-cause mortality 31% RRR in all-cause mortality with ICD (P=0.016); absolute RR 6%
DINAMIT[6] Recent (6–40 days) MI, EF≤35%, abnormal HRV or elevated average HR on 24-h Holter, NYHA class I–III 674 Conventional therapy All-cause mortality No difference in all-cause mortality; 58% RRR from arrhythmia with ICD (P=0.009)
SCD-HeFT[7] EF≤35%, (ischemic or nonischemic) NYHA class II–III 2521 Conventional therapy±amiodarone All-cause mortality 23% RRR in all-cause mortality with ICD (P=0.007); absolute RR 7%
EF indicates ejection fraction; NSVT, nonsustained VT; EPS, electrophysiological study; NYHA, New York Heart Association; RRR, relative risk reduction; RR, risk reduction; CABG, coronary artery bypass grafting; SAECG, signal-averaged ECG; HRV, heart rate variability; and HR, heart rate.

References

  1. Passman R and Kadish A. Sudden death prevention with implantable devices. Circulation. 2007 Jul 31;116(5):561-71. DOI:10.1161/CIRCULATIONAHA.106.655704 | PubMed ID:17664385 | HubMed [Passman]
  2. Moss A, Hall W, Cannom D, Daubert J, Higgins S, Klein H, Levine J, Saksena S, Waldo A, Wilber D, Brown M, Heo M; Multicenter Automatic Defibrillator Implantation Trial Investigators. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med. 1996;335:1933–1940.

    [35]
  3. Bigger J; Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. N Engl J Med. 1997;337:1569 –1575.

    [36]
  4. Buxton A, Lee K, DiCarlo L, Gold M, Greer G, Prystowsky E, O’Toole M, Tang A, Fisher J, Coromilas J, Talajic M, Hafley G; Multicenter Unsustained Tachycardia Trial Investigators. Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. N Engl J Med. 2000;342:1937–1945.

    [37]
  5. Moss A, Zareba W, Hall W, Klein H, Wilber D, Cannom D, Daubert J, Higgins S, Brown M, Andrews M; for the MADIT II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–883.

    [39]
  6. Hohnloser S, Kuck KH, Dorian P, Roberts R, Hampton J, Hatala R, Fain E, Gent M, Connolly S; DINAMIT Investigators. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med. 2004;351:2481–2488.

    [38]
  7. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH, and Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005 Jan 20;352(3):225-37. DOI:10.1056/NEJMoa043399 | PubMed ID:15659722 | HubMed [34]

All Medline abstracts: PubMed | HubMed